Spyre Therapeutics, Inc.SYRENASDAQ
LOADING
|||
EBITDA Over Time
Trending lower, below historical average, strong compound growth.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$-207.97M
↓ 179% below average
Average (9y)
$-74.47M
Historical baseline
Range
High:$-11.23M
Low:$-207.97M
CAGR
+38.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-207.97M | -63.0% |
| 2023 | $-127.60M | -54.1% |
| 2022 | $-82.82M | -29.3% |
| 2021 | $-64.07M | +19.2% |
| 2020 | $-79.27M | -2.5% |
| 2019 | $-77.35M | -71.2% |
| 2018 | $-45.17M | -64.7% |
| 2017 | $-27.43M | -26.0% |
| 2016 | $-21.77M | -94.0% |
| 2015 | $-11.23M | - |